N,N-dimethyl-2-(2-amino-4-fluorophenylthio)benzylamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10265481 |
| CHEMBL ID | 190860 |
| CHEBI ID | 125631 |
| SCHEMBL ID | 1643432 |
| MeSH ID | M0452115 |
| Synonym |
|---|
| CHEBI:125631 |
| 2-(2-dimethylaminomethyl-phenylsulfanyl)-5-fluoro-phenylamine |
| n-{2-[(2-amino-4-fluorophenyl)thio]benzyl}-n,n-dimethylamine |
| bdbm50164469 |
| CHEMBL190860 , |
| AKOS015963614 |
| BRD-K76108747-001-01-1 |
| ODXYYPIOITXURW-UHFFFAOYSA-N |
| n,n-dimethyl-2-(2-amino-4-fluorophenylthio)benzylamine |
| SCHEMBL1643432 |
| Q27216242 |
| 2-[[2-[(dimethylamino)methyl]phenyl]thio]-5-fluoroaniline |
| 2-[2-[(dimethylamino)methyl]phenyl]sulfanyl-5-fluoroaniline |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In the rats neither the single dose nor the five daily doses of 4-F-ADAM produced overt adverse effects clinically." | ( Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Chou, TK; Chu, TC; Fu, YK; Huang, WS; Huang, YY; Ma, KH; Mirsalis, JC; Ng, H; Shiue, CY; Tseng, TW, 2010) | 0.36 |
| "Toxicity studies in Sprague-Dawley rats and radiation dosimetry studies in Formosa Rock monkeys suggested that 4-[(18)F]-ADAM is safe for use in human PET imaging studies." | ( Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Chou, TK; Chu, TC; Fu, YK; Huang, WS; Huang, YY; Ma, KH; Mirsalis, JC; Ng, H; Shiue, CY; Tseng, TW, 2010) | 0.36 |
| Class | Description |
|---|---|
| aryl sulfide | Any organic sulfide in which the sulfur is attached to at least one aromatic group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.1417 | 0.0003 | 1.4656 | 10.0000 | AID239411 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.0015 | 0.0000 | 0.7048 | 8.1930 | AID239342 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 10.0000 | 0.0002 | 1.1115 | 8.0280 | AID239293 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.25%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||